At the news
? MIXEDIMPACT 7/10 8-K filed Feb 25, 2026 at 07:34 ET
Charles River Laboratories announced the planned divestiture of its CDMO and Cell Solutions businesses to GI Partners for contingent payments, and certain European Discovery Services assets to IQVIA for $145 million in cash plus up to $10 million in additional payments. The company updated its 2026 guidance, expecting the transactions to reduce reported revenue by over $200 million but improve non-GAAP EPS by ~$0.10 and add 100 basis points to non-GAAP operating margin.
- Divesting CDMO and Cell Solutions businesses to GI Partners for future contingent payments; combined 2025 revenue of $143 million
- Divesting European Discovery Services assets to IQVIA for $145 million cash plus up to $10 million in additional payments; 2025 revenue of $144 million
- Both transactions expected to close in Q2 2026
- Planned divestitures to reduce 2026 reported revenue by slightly more than $200 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access